To no great surprise, the U.K.’s health technology assessment body has found that the benefits of the first two approved ...

And more pharma news updates from Pharmalittle.

NICE said it made every effort to support reimbursement for Kisunla and Leqembi, but found the medicines are “not good value ...

UK health technology assessor the National Institute for Health and Care Excellence (NICE) has announced that Japanese ...

However, in both cases, NICE immediately published draft guidance that concluded the anti-amyloid drugs were too expensive to ...

A U.K. health agency said the Alzheimer's drugs Kisunla and Leqembi are not cost-effective, meaning they won't be offered through the NHS.

See here for Eisai (ESALF) stock analysis including Leqembi's EU approval, growth potential, and industry valuation amid ...

Most recently, the drug pulled around 13.3 billion Japanese yen ($87 million) in the third quarter of Eisai’s 2024 fiscal year, which will end March 31. Leqembi collected sales of 29.6 billion ...

Reflecting on Eisai’s Alzheimer’s disease development journey—from Aricept’s U.S. launch in 1997 to Leqembi nearly a quarter century later—the company’s CEO Haruo Naito on Wednesday ...

Dec 23 (Reuters) - An influential drug pricing research group said Eisai Co Ltd (4523.T), opens new tab and Biogen Inc's (BIIB.O), opens new tab new Alzheimer's disease treatment lecanemab should ...

SAN FRANCISCO, Nov 30 (Reuters) - Japan's Eisai Co (4523.T), opens new tab plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed ...

In August, Eisai Inc. cut the ribbon on a 15-story, 332,800-square-foot space that serves as the hub for the company, which is the U.S. pharmaceutical subsidiary of Tokyo-based Eisai Co. Ltd ...